Kirk (Jay Baruchel, 'Beim ersten Mal' und 'Tropic Thunder'), ein Durchschnittstyp, kann sein Glück nicht fassen, als sich Molly (Alice Eve), eine erfolgreiche und überaus attraktive Traumfrau, in ihn verliebt. Jetzt ist es an ihm, diese Frau zu halten, denn sie ist 'Zu scharf, um wahr zu sein'. Ab 29. April im Kino.
Ich bin die Märtyrerin Reem Saleh Riyashi; ich hoffte, dass meine zerstückelten Körperteile zu Granatsplittern werden, die die Zionisten in Stücke reissen, die mit den Schädeln der Zionisten an die Tore des Himmels klopfen. Wie oft habe ich meiner Seele gesagt: "Oh Seele, wenn du die Zionisten hasst, die Feinde meiner Religion, soll mein Blut meinen Weg in den Himmel ebnen. Seit dem 8. Schuljahr habe ich daraufhingearbeitet, täglich Menschen gesucht, die mich leiten können, mit zuhören und mir helfen könne. Wie oft habe ich mir gewünscht, einen Shahada-bringenden (Selbstmord)Angriff in Israel durchzuführen; durch meine Hartnäckigkeit und Allahs Hilfe ist mein Wunsch in Erfüllung gegangen.
Mama, was trägst du auf dem Arm, anstatt mich zu halten? Reem baut Bomben Mama, was trägst du auf dem Arm, antatt mich zu halten? Mutter versteckt die Bomben Ein Spielzeug oder ein Geschenk für mich? Mama Reem! Warum trägst du deinen Schleier? Gehst du weg Mama? Komm schnell wieder Mama Das Mädchen sieht die Nachricht über den Bombenanschlag seiner Mutter Meine Mutter! Meine Mutter! Anstatt mich im Arm zu halten, trugst du eine Bombe. Erst jetzt verstehe ich, was wichtiger ist als wir. Meine Liebe (zu Mohammed) ist nicht nur leeres Gerede. Ich folge meiner Mama auf ihrem Weg! Meine Mutter! Meine Mutter! (Holt Sprengstoff aus der Schublade der Mutter) Meine Mutter! Meine Mutter!
The Crespo family of Detroit, Mich. was named winner of the third annual National Family PLUS Cook-off, which was hosted at Bradford’s on Bishop in Atlanta by Boys & Girls Clubs of America (BGCA) and Kimberly-Clark Corporation on Wednesday, Nov. 17. Families representing Boys & Girls Clubs from around the nation competed in regional events to qualify for the national cook-off. Finalists represented Clubs from Harbor City, Calif.; Pittsburgh, Pa.; Detroit, Mich.; Bluffton, S.C.; and Swink, Okla.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bgca/47039/
Life with our four-legged friends is so much fun that it inspired dog owners across the country to write a jingle about it. Yesterday, Country Music star Trace Adkins selected Dewey Longuski of Mason, Mich. as the Grand Prize winner of the Waggin’ Train® Tail Waggin’ Jingle Contest, which asked dog owners to create an original jingle with lyrics describing how they enjoy a “tail waggin’ good time” with their best buddies. As the Grand Prize winner of the national contest, Longuski won the opportunity of a lifetime to perform his jingle in a recording session produced by the Country star.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53057-trace-adkins-names-grand-prize-winner-waggin-train-jingle-contest
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
